首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   56篇
  免费   1篇
  国内免费   2篇
基础医学   3篇
口腔科学   2篇
临床医学   1篇
内科学   2篇
皮肤病学   27篇
特种医学   1篇
综合类   8篇
药学   12篇
中国医学   1篇
肿瘤学   2篇
  2023年   1篇
  2020年   1篇
  2019年   2篇
  2018年   1篇
  2016年   2篇
  2014年   3篇
  2013年   6篇
  2012年   3篇
  2010年   3篇
  2009年   3篇
  2008年   5篇
  2007年   2篇
  2006年   6篇
  2005年   4篇
  2004年   3篇
  2003年   2篇
  2002年   6篇
  2000年   1篇
  1999年   5篇
排序方式: 共有59条查询结果,搜索用时 31 毫秒
1.
Long-term use of corticosteroids or local use of tazarotene (TAZ) alone for the treatment of psoriasis cause safety issues and low compliance rates. Combining these two may optimize their efficacy and minimize safety concerns. This study aimed to evaluate the clinical efficacy and safety of a fixed combination of TAZ 0.05% and betamethasone dipropionate 0.05% (BM) for psoriasis vulgaris. A multicenter, randomized, single-blinded, controlled phase 3 clinical trial was conducted. A total of 600 Chinese subjects with psoriasis vulgaris were randomized (3:1:1) to TAZ/BM cream, TAZ gel or BM cream groups for 6 weeks with an 8-week follow up. The primary efficacy assessment end-point was 75% improvement in Psoriasis Area and Severity Index (PASI-75) at 6 weeks. Secondary outcome assessments included PASI-90, percentage of PASI decrease and so forth. Safety and treatment-related adverse events were monitored throughout the study. Our results demonstrated that the TAZ/BM group exhibited statistically significant superiority in PASI-75 over TAZ (6.74% vs 1.67%) within 2 weeks. After 6 weeks of treatment, PASI-75 was 44.94% in the TAZ/BM group while 19.17% and 35.00% in the TAZ and BM group, respectively. At the 8-week follow up, the relapse rate of the TAZ/BM group was significantly lower than the BM group (10.62% vs 29.63%, P = 0.0269) though comparable with the TAZ group (10.00%). The most frequently reported treatment-related adverse event was mild to moderate level of skin irritation events. TAZ/BM combination has significant advantages over TAZ, including satisfying efficacy, rapid onset and reduced local stimulation. Meanwhile, compared with BM, it has the advantages of longer relief time and reduced clinical relapse rate. The TAZ/BM combination drug provides psoriatic patients an alternative drug with high efficacy and low relapse rate and safety concerns.  相似文献   
2.
目的 探讨他扎罗汀倍他米松乳膏(含0.05%他扎罗汀和0.05%二丙酸倍他米松)治疗慢性斑块型银屑病的临床疗效和安全性。方法 将90例慢性斑块型银屑病患者随机分为治疗组(45例)和对照组(45例),治疗组外用他扎罗汀倍他米松乳膏,每日1次,睡前应用;对照组外用卡泊三醇软膏,早晚各1次;疗程均为4周。疗程结束后,随访8周。结果 治疗4周后,治疗组的银屑病皮损面积和严重程度指数(psoriasis area severity index, PASI)、医生对病情的总体评估(physician’s global assessment, PGA)和皮肤病生活质量指数(dermatology life quality index, DLQI)均较对照组显著下降,差异有统计学意义(P<0.05)。治疗组的有效率(65.00%)显著高于对照组(41.46%),差异有统计学意义(P<0.05)。治疗过程中,两组间不良反应发生率差异无统计学意义(P>0.05)。随访8周后,治疗组的复发率为23.07%,对照组为29.41%,差异无统计学意义(P>0.05)。结论 他扎罗汀倍他米松乳膏治疗慢性斑块型银屑病的疗效优于卡泊三醇软膏,不良反应和复发率与卡泊三醇软膏没有差异。  相似文献   
3.
Tazarotene (Tazorac®, Allergan, Inc.) is the first topical retinoid approved for the treatment of plaque psoriasis. It has a similar onset of action compared to potent topical steroids and has the advantage of a longer remission. The common side effects associated with the drug include skin irritation (including pruritus), erythema and a burning sensation. To overcome some of these shortcomings, it has been used in combination with steroids, calcipotriene and phototherapy. Combination therapy not only results in a decrease in adverse side effects, but also enhanced efficacy. Clinical study data have shown that combination therapy is just as important as tazarotene monotherapy, if not more.  相似文献   
4.
目的观察窄谱中波紫外线(NB-UVB)联合他扎罗汀凝胶外用治疗寻常型银屑病的疗效及安全性。方法对50例中重度患者采用NB-UVB每周3次照射配合0.05%他扎罗汀凝胶每晚1次外用,共治疗8周,用PASI积分评价疗效。结果 治疗开始后1~2周出现疗效,随着治疗时间的延长,有效率逐渐提高,疗程结束时治愈率92%,有效率达100%,8例发生皮肤刺激反应,占16%。结论 NB-UVB照射联合他扎罗汀凝胶外用治疗寻常型银屑病具有良好疗效及安全性。  相似文献   
5.
Skin, being exposed directly to the environment, represents a unique model for demonstrating the synergistic effects of intrinsic and extrinsic factors on the ageing process. Ultraviolet radiation (UVR) is the major factor among exogenous stressors responsible for premature skin ageing. The problem of skin ageing has captured public attention and has an important social impact. Different therapeutic approaches have been developed to treat cutaneous ageing and to diminish or prevent the negative effects of UVR. Topical retinoids represent an important and powerful class of molecules in the dermatologist’s hands for the treatment of photodamaged skin. Since their introduction more than 20 years ago, topical retinoids have shown beneficial efficacy and good safety profiles in the management of photodamaged skin, and as therapeutic anti‐ageing agents. This review provides a brief retrospective of the development of topical retinoids in the treatment of photodamaged skin, elucidates their mechanism of action, delineates their use and addresses clinical, pharmaceutical and regulatory issues in connection with their intended use.  相似文献   
6.
Effect of topical tazarotene in the treatment of congenital ichthyoses   总被引:5,自引:0,他引:5  
The clinical efficacy and tolerability of the topical receptor-selective retinoid tazarotene in the treatment of congenital ichthyoses was investigated. Twelve consecutive patients with different forms of congenital ichthyosis were enrolled in an open, non-randomized, intraindividually controlled, half-side pilot study. Diagnoses were X-linked recessive ichthyosis, non-erythrodermic autosomal recessive lamellar ichthyosis, autosomal dominant ichthyosis vulgaris and ichthyosis bullosa of Siemens (IBS). Tazarotene 0.05% gel was applied unilaterally daily on a defined body area measuring 10% of the body surface area. The contralateral side was treated with an ointment containing 10% urea. After 14 days, application frequency was reduced to three times a week, and stopped after another 2 weeks. The follow-up period was 3 months. Reduction in scaling and roughness was used to assess the clinical response in the tazarotene-treated area compared with the control area. Clinical and laboratory assessments were performed every 14 days during the trial. Unilateral improvement in favour of the tazarotene-treated side was observed in nine of 12 patients (75%). Four patients (33%) achieved an excellent response and four (33%) achieved a good response. No therapeutic effect was seen in patients with IBS. The remission persisted during the reduction phase and after discontinuation for up to 2 months. Local irritation in three patients was the only side-effect detectable. Short-term topical application of tazarotene 0.05% gel is a very effective and well-tolerated treatment modality in different forms of congenital ichthyoses and may be an alternative to systemic retinoid therapy.  相似文献   
7.
Chronic sun exposure leads to photodamage, which is characterized clinically by fine and coarse wrinkles, dyspigmentation, telangiectasia, laxity, roughness and a sallow appearance. Many treatments claim to reduce the signs of photodamage, however evidence from randomized controlled trials (RCT) to support these claims is limited. The use of topical retinoids, particularly tretinoin, isotretinoin and tazarotene, has been shown to significantly reduce signs of photodamage both clinically and histologically. Over recent years a number of RCTs, have affirmed that topical tazarotene is an effective and safe treatment for photodamaged skin.  相似文献   
8.
Aging of skin is an intricate biological process consisting of two types. While intrinsic or chronological aging is an inevitable process, photoaging involves the premature aging of skin occurring due to cumulative exposure to ultraviolet radiation. Chronological and photoaging both have clinically differentiable manifestations. Various natural and synthetic retinoids have been explored for the treatment of aging and many of them have shown histological and clinical improvement, but most of the studies have been carried out in patients presenting with photoaged skin. Amongst the retinoids, tretinoin possibly is the most potent and certainly the most widely investigated retinoid for photoaging therapy. Although retinoids show promise in the treatment of skin aging, irritant reactions such as burning, scaling or dermatitis associated with retinoid therapy limit their acceptance by patients. This problem is more prominent with tretinoin and tazarotene whereas other retinoids mainly represented by retinaldehyde and retinol are considerably less irritating. In order to minimize these side effects, various novel drug delivery systems have been developed. In particular, nanoparticles have shown a good potential in improving the stability, tolerability and efficacy of retinoids like tretinoin and retinol. However, more elaborate clinical studies are required to confirm their advantage in the delivery of topical retinoids.  相似文献   
9.
目的 探讨他扎罗汀在进行期寻常型银屑病中的作用机制。方法 将43例进行期寻常型银屑病患者随机分为他扎罗汀治疗组及对照组.用原位杂交的方法检测进行期银屑病皮损外用他扎罗汀治疗前后的早幼粒细胞白血病(PML)基因mRNA的表达。结果 在银屑病治疗组皮损中,可见PML不仅表达于基底层(86.96%),且以灶状表达于基底上层(78.26%);他扎罗汀治疗后14d全层几乎无PMLmRNA表达(基底层为8.69%,基底上层为4.35%)。对照组处理前后PML基因表达无明显变化。结论 他扎罗汀可能通过下调进行期银屑病表皮中PML基因的表达来抑制表皮角质形成细胞的异常增殖。  相似文献   
10.
OBJECTIVE: The rationale for using tazarotene in oral lichen planus (OLP) is its regulatory action on the growth and differentiation of keratinocytes and on inflammation. This randomized, placebo-controlled study addresses evaluation of the effects of topic tazarotene in the treatment of OLP. DESIGN: The degree of lesions before and after treatment scored by a 6-score scale in six cases treated with tazarotene was statistically compared with those of six controls treated with placebo. SUBJECTS: Twelve patients with hyperkeratosic OLP were randomly allocated to treatment with tazarotene gel 0.1% b.i.d. or with placebo for eight consecutive weeks. METHODS: The statistical comparison was executed by means of Wilcoxon analysis for paired data. RESULTS: Patients treated with tazarotene presented a significant reduction of their lesions as compared with the control group. Among transitory side-effects, burning sensation and taste abnormalities were observed. CONCLUSION: Topical tazarotene may be a valuable therapeutic tool in the treatment of hyperkeratotic OLP.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号